[go: up one dir, main page]

MX2009006873A - Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida. - Google Patents

Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.

Info

Publication number
MX2009006873A
MX2009006873A MX2009006873A MX2009006873A MX2009006873A MX 2009006873 A MX2009006873 A MX 2009006873A MX 2009006873 A MX2009006873 A MX 2009006873A MX 2009006873 A MX2009006873 A MX 2009006873A MX 2009006873 A MX2009006873 A MX 2009006873A
Authority
MX
Mexico
Prior art keywords
wet granulation
solid dose
disintegrant
formula
dosage form
Prior art date
Application number
MX2009006873A
Other languages
English (en)
Inventor
David Harris
Zhi Yun Wang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009006873A publication Critical patent/MX2009006873A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una forma de dosificación sólida de desintegración rápida que comprende un ingrediente farmacéutico activo, un desintegrador y un promotor de desintegración, cuya formulación se puede obtener mediante un procedimiento de granulación húmeda; en una modalidad ejemplificada, el agente farmacéutico activo es un antagonista del receptor de trombina, el desintegrador es croscarmelosa de sodio, y el promotor de desintegración es silicato de calcio; en algunas modalidades, el antagonista del receptor de trombina está representado por la fórmula: (ver fórmula) o su sal farmacéuticamente aceptable; también se describen métodos para tratar pacientes en riesgo de síndrome coronario agudo mediante la administración de dicha forma de dosificación sólida de desintegración rápida.
MX2009006873A 2006-12-22 2007-12-19 Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida. MX2009006873A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87160506P 2006-12-22 2006-12-22
PCT/US2007/025996 WO2008079260A2 (en) 2006-12-22 2007-12-19 Disintegration promoters in solid dose wet granulation formulations

Publications (1)

Publication Number Publication Date
MX2009006873A true MX2009006873A (es) 2009-07-03

Family

ID=39467196

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006873A MX2009006873A (es) 2006-12-22 2007-12-19 Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.

Country Status (6)

Country Link
US (1) US20080194560A1 (es)
EP (1) EP2120879A2 (es)
JP (1) JP2010513516A (es)
CA (1) CA2673228A1 (es)
MX (1) MX2009006873A (es)
WO (1) WO2008079260A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
CN101465825B (zh) * 2008-12-31 2012-07-11 阿里巴巴集团控股有限公司 即时通信的方法、即时通信服务器、语音服务器及系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304773A (en) * 1980-06-26 1981-12-08 E. R. Squibb & Sons, Inc. Novel bendroflumethiazide formulations and method
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
WO2001000656A2 (en) * 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
CZ20024098A3 (cs) * 2000-06-15 2003-05-14 Schering Corporation Látky, antagonizující receptor thrombinu
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US6521270B1 (en) * 2001-06-11 2003-02-18 The Procter & Gamble Company Compositions comprising nitrofurantoin and uva ursi
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
MY139335A (en) * 2001-10-18 2009-09-30 Schering Corp Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists
ATE455774T1 (de) * 2002-04-16 2010-02-15 Schering Corp Trizyklische thrombinrezeptorantagonisten
JP2004238348A (ja) * 2003-02-07 2004-08-26 Fuji Pharmaceutical Co Ltd 経口投与用イトラコナゾール製剤
DE10317816A1 (de) * 2003-04-16 2004-11-04 Claas Selbstfahrende Erntemaschinen Gmbh Feldhäcksler mit positionierbarer Fahrerkabine
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
MX2009000150A (es) * 2006-06-30 2009-01-23 Schering Corp Formulaciones de dosis solida de un antagonista del receptor de trombina.
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist

Also Published As

Publication number Publication date
US20080194560A1 (en) 2008-08-14
CA2673228A1 (en) 2008-07-03
JP2010513516A (ja) 2010-04-30
WO2008079260A3 (en) 2008-09-25
EP2120879A2 (en) 2009-11-25
WO2008079260A2 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
ES2923214T3 (es) Composición farmacéutica que comprende mesilato de lenvatinib
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
MX364937B (es) Composiciones farmaceuticas de acido 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico y su administracion.
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
HRP20250604T1 (hr) Formulacije tableta neratinib maleata
JP2014533733A5 (es)
CR8047A (es) Procedimiento de tratamiento de la arterosclerosis, dislipidemias y afecciones relacionadas y composiciones farmaceuticas
CA2601955A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
MX2009003360A (es) Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
NZ591408A (en) Paracetamol and Calcium carbonate composition
RU2013154355A (ru) Способ лечения мезотелиомы ингибитором рi3к
JP2016512234A (ja) 薬学的複合製剤
CA2529604A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
MX2012002681A (es) Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades.
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
GB2446341A (en) Method and system for transdermal drug delivery
MX2009006873A (es) Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
US20110319464A1 (en) Methods for treating benign prostatic hyperplasia
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
MX2007010886A (es) Metodos y formulaciones de acarbosa para tratar constipacion cronica.
RU2008115582A (ru) Фармацевтическая композиция для лечения болезни паркинсона

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal